Is P21 FDA approved?
No. This profile records P21 as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE NEUROGENESIS BOOSTER
Neurotrophic Peptide P21; CNTF Analog
P21 is an engineered peptide based on ciliary neurotrophic factor (CNTF) that can cross the blood-brain barrier and promote neurogenesis, the growth of new brain cells. It boosts BDNF (brain-derived neurotrophic factor) and has shown promise for cognitive enhancement, Alzheimer's prevention, and stroke recovery.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
Aug 28, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records P21 as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 10 mg daily (subcutaneous, intramuscular, or oral).
Schedule: daily. Cycle: 8 weeks on, 8 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Promotes growth of new neurons in the hippocampus
Upregulates brain-derived neurotrophic factor
Reduces amyloid-beta and tau pathology
Enhances NMDA receptor activity for learning
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.